Search Results - "Francesco, Facchinetti"

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors by Facchinetti, Francesco, Hollebecque, Antoine, Bahleda, Rastislav, Loriot, Yohann, Olaussen, Ken A, Massard, Christophe, Friboulet, Luc

“…Precision oncology relies on the identification of molecular alterations, responsible for tumor initiation and growth, which are suitable targets of specific…”
Get full text

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors by Leonetti, Alessandro, Facchinetti, Francesco, Zielli, Teresa, Brianti, Elena, Tiseo, Marcello

Get full text

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers by Facchinetti, Francesco, Loriot, Yohann, Kuo, Mei-Shiue, Mahjoubi, Linda, Lacroix, Ludovic, Planchard, David, Besse, Benjamin, Farace, Françoise, Auger, Nathalie, Remon, Jordi, Scoazec, Jean-Yves, André, Fabrice, Soria, Jean-Charles, Friboulet, Luc

“…The identification of molecular mechanisms conferring resistance to tyrosine kinase inhibitor (TKI) is a key step to improve therapeutic results for patients…”
Get full text

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC by Mazzaschi, Giulia, Facchinetti, Francesco, Missale, Gabriele, Canetti, Diana, Madeddu, Denise, Zecca, Alessandra, Veneziani, Michele, Gelsomino, Francesco, Goldoni, Matteo, Buti, Sebastiano, Bordi, Paola, Aversa, Franco, Ardizzoni, Andrea, Quaini, Federico, Tiseo, Marcello

“…•Immune checkpoint blockade (ICB) has shown unprecedented results in NSCLC.•Immune profiles predictive of ICB efficacy have not been entirely assessed.•Tissue…”
Get full text

The efficacy of immune checkpoint inhibitors in thoracic malignancies by Remon, Jordi, Facchinetti, Francesco, Besse, Benjamin

“…The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In…”
Get full text

New pathways in immune stimulation: targeting OX40 by Alves Costa Silva, Carolina, Facchinetti, Francesco, Routy, Bertrand, Derosa, Lisa

“…Immune checkpoint blockers (ICB) reinvigorate the immune system by removing the molecular brakes responsible for the scarce activity of immune phenotypes…”
Get full text

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System by Sisi, Monia, Fusaroli, Michele, De Giglio, Andrea, Facchinetti, Francesco, Ardizzoni, Andrea, Raschi, Emanuel, Gelsomino, Francesco

“…Background The development of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has improved the survival outcomes of patients with advanced…”
Get full text

Non-small-cell lung cancer: how to manage BRAF -mutated disease by Guaitoli, Giorgia, Zullo, Lodovica, Tiseo, Marcello, Dankner, Matthew, Rose, April An, Facchinetti, Francesco

“…mutations are reported in about 3-5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three…”
Get full text

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development by Vasseur, Damien, Bigot, Ludovic, Beshiri, Kristi, Flórez-Arango, Juan, Facchinetti, Francesco, Hollebecque, Antoine, Tselikas, Lambros, Aldea, Mihaela, Blanc-Durand, Felix, Gazzah, Anas, Planchard, David, Lacroix, Ludovic, Pata-Merci, Noémie, Nobre, Catline, Da Silva, Alice, Nicotra, Claudio, Ngo-Camus, Maud, Braye, Floriane, Nikolaev, Sergey I, Michiels, Stefan, Jules-Clement, Gérôme, Olaussen, Ken André, André, Fabrice, Scoazec, Jean-Yves, Barlesi, Fabrice, Ponce, Santiago, Soria, Jean-Charles, Besse, Benjamin, Loriot, Yohann, Friboulet, Luc

“…Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy,…”
Get full text

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib by Gozzi, Fabrizio, Tiseo, Marcello, Facchinetti, Francesco, Gandolfi, Stefano, Rubino, Pierangela

“…We describe the case of Gefitinib-related bilateral corneal perforation. An 86-year-old female patient had bilateral painless and progressive vision loss due…”
Get full text

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors by Dall’Olio, Filippo G., Abbati, Francesca, Facchinetti, Francesco, Massucci, Maria, Melotti, Barbara, Squadrilli, Anna, Buti, Sebastiano, Formica, Francesca, Tiseo, Marcello, Ardizzoni, Andrea

“…Aims: To assess prognostic value of pre-therapy carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) blood levels in non-small cell lung…”
Get full text

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report by Bersanelli, Melissa, Facchinetti, Francesco, Tiseo, Marcello, Maiorana, Mariarosa, Buti, Sebastiano

“…Sporadic data are available about pazopanib use in patients with metastatic renal cell carcinoma (mRCC) undergoing dialysis and no systematic review has been…”
Get more information

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors by Facchinetti, Francesco, Tiseo, Marcello, Di Maio, Massimo, Graziano, Paolo, Bria, Emilio, Rossi, Giulio, Novello, Silvia

“…Crizotinib is an oral inhibitor of anaplastic lymphoma kinase (ALK) with remarkable clinical activity in patients suffering from ALK -rearranged non-small cell…”
Get full text

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives by Facchinetti, Francesco, Bordi, Paola, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello

“…Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents an affirmed reality in the treatment of advanced non-small-cell lung cancer…”
Get full text

Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients by Vasseur, Damien, Arbab, Ahmadreza, Giudici, Fabiola, Marzac, Christophe, Michiels, Stefan, Tagliamento, Marco, Bayle, Arnaud, Smolenschi, Cristina, Sakkal, Madona, Aldea, Mihaela, Sassi, Hela, Dall’Olio, Filippo Gustavo, Pata-Merci, Noémie, Cotteret, Sophie, Fiévet, Alice, Auger, Nathalie, Friboulet, Luc, Facchinetti, Francesco, Géraud, Arthur, Ponce, Santiago, Hollebecque, Antoine, Besse, Benjamin, Micol, Jean Baptiste, Italiano, Antoine, Lacroix, Ludovic, Rouleau, Etienne

“…Next-generation sequencing (NGS) assays based on plasma cell-free DNA (cfDNA) are increasingly used for clinical trials inclusion. Their optimized limit of…”
Get full text

YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs by Minari, Roberta, Valentini, Samuel, Madeddu, Denise, Cavazzoni, Andrea, La Monica, Silvia, Lagrasta, Costanza Anna Maria, Bertorelli, Roberto, De Sanctis, Veronica, Fassan, Paola, Azzoni, Cinzia, Bottarelli, Lorena, Frati, Caterina, Gnetti, Letizia, Facchinetti, Francesco, Petronini, Pier Giorgio, Alfieri, Roberta, Romanel, Alessandro, Tiseo, Marcello

“…ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs. Here, we…”
Get full text

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report by Enrico, Diego, Lacroix, Ludovic, Chen, Jeanne, Rouleau, Etienne, Scoazec, Jean-Yves, Loriot, Yohann, Tselikas, Lambros, Jovelet, Cécile, Planchard, David, Gazzah, Anas, Mezquita, Laura, Ngo-Camus, Maud, Michiels, Stefan, Massard, Christophe, Recondo, Gonzalo, Facchinetti, Francesco, Remon, Jordi, Soria, Jean-Charles, André, Fabrice, Vassal, Gilles, Friboulet, Luc, Besse, Benjamin

“…Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by…”
Get full text

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? by Recondo, Gonzalo, Facchinetti, Francesco, Olaussen, Ken A., Besse, Benjamin, Friboulet, Luc

“…The traditional approach to the treatment of patients with advanced-stage non-small-cell lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations…”
Get full text

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall by Leonetti, Alessandro, Facchinetti, Francesco, Rossi, Giulio, Minari, Roberta, Conti, Antonia, Friboulet, Luc, Tiseo, Marcello, Planchard, David

“…•BRAF mutations, accounting for about 2% of NSCLC, can be divided in V600E and non-V600E.•Dabrafenib and trametinib are FDA and EMA approved for the treatment…”
Get full text

Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC by Perrone, Fabiana, Leonetti, Alessandro, Tiseo, Marcello, Facchinetti, Francesco

Get more information